推荐产品
等级
certified reference material
形式
liquid
特点
Snap-N-Spike®/Snap-N-Shoot®
包装
ampule of 1 mL
制造商/商品名称
Cerilliant®
浓度
1.0 mg/mL in methanol
技术
gas chromatography (GC): suitable
liquid chromatography (LC): suitable
应用
pharmaceutical (small molecule)
格式
single component solution
储存温度
2-8°C
SMILES字符串
CN1C(=O)N(C)c2nc[nH]c2C1=O
InChI
1S/C7H8N4O2/c1-10-5-4(8-3-9-5)6(12)11(2)7(10)13/h3H,1-2H3,(H,8,9)
InChI key
ZFXYFBGIUFBOJW-UHFFFAOYSA-N
基因信息
human ... ADORA1(134) , ADORA2A(135) , ADORA2B(136) , ADORA3(140) , PDE3A(5139) , PDE3B(5140) , PDE4A(5141) , PDE4B(5142) , PDE4C(5143) , PDE4D(5144)
一般描述
A Certified Spiking Solution® suitable for use as starting material in the preparation of calibrators and controls for theophylline testing methods by LC-MS/MS or GC-MS. Theophylline, also known as dimethylxanthine, is a naturally occurring stimulant of the xanthine family. Sold under the trade name Theolair, theophylline is used for treatment of asthma and other respiratory diseases.
法律信息
CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
CERTIFIED SPIKING SOLUTION is a registered trademark of Cerilliant Corporation
Snap-N-Shoot is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany
相关产品
产品编号
说明
价格
警示用语：
Danger
危险分类
Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Flam. Liq. 2 - STOT SE 1
靶器官
Eyes,Central nervous system
WGK
WGK 2
闪点(°F)
49.5 °F
闪点(°C)
9.7 °C
法规信息
危险化学品
Bing Dai et al.
American journal of kidney diseases : the official journal of the National Kidney Foundation, 60(3), 360-370 (2012-04-21)
Whether treatment with adenosine receptor antagonists such as theophylline can prevent contrast-induced acute kidney injury (AKI) remains controversial. We conducted a meta-analysis of randomized controlled trials using MEDLINE (1966 to July 2011), EMBASE (1980 to July 2011), Web of Science
Mazen Al-Alawi et al.
The American journal of medicine, 127(5), 370-378 (2014-01-02)
Global estimates on aging predict an increased burden of asthma in the older population. Consequently, its recognition, diagnosis, and management in clinical practice require optimization. This review aims to provide an update for clinicians, highlighting advances in the understanding of
F S F Ram et al.
Respiratory medicine, 99(2), 135-144 (2005-02-18)
To determine the efficacy of oral theophylline compared with placebo in people with stable chronic obstructive pulmonary disease (COPD). Systematic review of randomized-controlled trials comparing oral theophylline with placebo for a minimum of 7 days in people with stable COPD.
David J Henderson-Smart et al.
The Cochrane database of systematic reviews, (1)(1), CD000273-CD000273 (2010-01-22)
Recurrent apnea is common in preterm infants, particularly at very early gestational ages. These episodes of loss of effective breathing can lead to hypoxemia and bradycardia, which may be severe enough to require resuscitation including use of positive pressure ventilation.
Victoria Boswell-Smith et al.
The Journal of allergy and clinical immunology, 117(6), 1237-1243 (2006-06-06)
Theophylline has been relegated to a second- or even third-line therapy in the treatment of asthma and chronic obstructive pulmonary disease (COPD), behind glucocorticosteroids and beta2-agonists, although recent findings have suggested that theophylline possesses anti-inflammatory and immunomodulatory effects in addition
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门